261 related articles for article (PubMed ID: 11001329)
21. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
22. Tigecycline.
Pankey GA
J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
[TBL] [Abstract][Full Text] [Related]
23. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.
van Ogtrop ML; Andes D; Stamstad TJ; Conklin B; Weiss WJ; Craig WA; Vesga O
Antimicrob Agents Chemother; 2000 Apr; 44(4):943-9. PubMed ID: 10722495
[TBL] [Abstract][Full Text] [Related]
24. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.
Jones RN
Diagn Microbiol Infect Dis; 1999 Nov; 35(3):249-52. PubMed ID: 10626138
[TBL] [Abstract][Full Text] [Related]
25. Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.
Johnson DM; Jones RN
Diagn Microbiol Infect Dis; 1996 Jan; 24(1):53-7. PubMed ID: 8988765
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
27. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
Sum PE; Petersen P
Bioorg Med Chem Lett; 1999 May; 9(10):1459-62. PubMed ID: 10360756
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
31. Case studies in current drug development: 'glycylcyclines'.
Sum PE
Curr Opin Chem Biol; 2006 Aug; 10(4):374-9. PubMed ID: 16807065
[TBL] [Abstract][Full Text] [Related]
32. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
35. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
Hoellman DB; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Apr; 44(4):1085-8. PubMed ID: 10722519
[TBL] [Abstract][Full Text] [Related]
36. Tigecycline: a critical analysis.
Stein GE; Craig WA
Clin Infect Dis; 2006 Aug; 43(4):518-24. PubMed ID: 16838243
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
Garrison MW; Mutters R; Dowzicky MJ
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
[TBL] [Abstract][Full Text] [Related]
38. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
Zhang YY; Zhou L; Zhu DM; Wu PC; Hu FP; Wu WH; Wang F
Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
